Market capitalization | $210.58m |
Enterprise Value | $224.72m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.25 |
P/S ratio (TTM) P/S ratio | 3.05 |
P/B ratio (TTM) P/B ratio | 14.66 |
Sales growth (TTM) Sales growth | 42.07% |
Turnover (TTM) Turnover | $69.07m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
7 Analysts have issued a NeuroPace Inc forecast:
7 Analysts have issued a NeuroPace Inc forecast:
Dec '23 |
+/-
%
|
||
Net profit | -33 -33 |
30%
30%
|
|
Depreciation and amortization | 1.61 1.61 |
46%
46%
|
|
Share compensation | 9.56 9.56 |
14%
14%
|
|
Operating cash flow | -20 -20 |
47%
47%
|
|
Investments | 0.17 0.17 |
72%
72%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -20 -20 |
47%
47%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Joel Becker |
Employees | 171 |
Founded | 1997 |
Website | www.neuropace.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.